A daptive and deficient growth of cardiac muscleillustrated, respectively, by hypertrophy after a hemodynamic load and by intractable pump failure after myocardial infarction-impose fundamental limits to contemporary clinical cardiology. Relatively little is known of the signaling molecules in the myocardium that might coordinate cardiac growth and morphogenesis during fetal life, communicate growth signals from the surface membrane to the nucleus, interact with genomic DNA to impel cell growth and alter the synthesis of muscle proteins, and, eventually, extinguish the ability of cardiac myocytes to proliferate. Potential candidates as regulators of myocardial growth and differentiation are the polypeptide growth factors,12 multifunctional proteins analogous to but distinct from the classic (hematogenous) hormones. The initial discovery of peptide growth factors can be traced to the fundamental observation that extracts of mouse submaxillary salivary gland support growth of the innervating sympathetic neurons.3 Subsequent purification of nerve and epidermal growth factors gave impetus to the search for other trophic compounds, to pursuit of their pleiotropic effects on cell growth and maturation, and to delineation of cellular pathways for growth factor signal transduction.
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Cardiac Myocytes as Targets for the Action of Peptide Growth Factors Michael D. Schneider, MD, and Thomas G. Parker, MD A daptive and deficient growth of cardiac muscleillustrated, respectively, by hypertrophy after a hemodynamic load and by intractable pump failure after myocardial infarction-impose fundamental limits to contemporary clinical cardiology. Relatively little is known of the signaling molecules in the myocardium that might coordinate cardiac growth and morphogenesis during fetal life, communicate growth signals from the surface membrane to the nucleus, interact with genomic DNA to impel cell growth and alter the synthesis of muscle proteins, and, eventually, extinguish the ability of cardiac myocytes to proliferate. Potential candidates as regulators of myocardial growth and differentiation are the polypeptide growth factors,12 multifunctional proteins analogous to but distinct from the classic (hematogenous) hormones. The initial discovery of peptide growth factors can be traced to the fundamental observation that extracts of mouse submaxillary salivary gland support growth of the innervating sympathetic neurons.3 Subsequent purification of nerve and epidermal growth factors gave impetus to the search for other trophic compounds, to pursuit of their pleiotropic effects on cell growth and maturation, and to delineation of cellular pathways for growth factor signal transduction.
Cardiac myocytes recently were demonstrated to be targets for the action of at least two sets of growth factors,4 the heparin-binding "fibroblast" growth factors (FGFs)2 and the type ,B transforming growth factors (TGFI3s),l which are the emphasis of this review. Relatively little is known of the possible role in ventricular muscle of other trophic peptides including platelet-derived growth factor (PDGF),s epidermal growth factor (EGF),3 and the insulinlike growth factors (IGFs), whose expression and effects in the cardiovascular system are characterized chiefly in vascular smooth muscle or the endothelium. The information in this review will be presented in six sequential parts: 1) an overview of the FGFs and TGF,Bs, 2) growth factor expression in normal and diseased myocardium, 3) mechanisms for transduction of growth factor effects by cellular oncogenes, 4) mechanisms for growth factor control of myocyte differentiation illustrated in the partially contrasting but relatively well-defined example of skeletal muscle, 5) action of growth factors during atherosclerosis and angiogenesis, and 6) recent evidence for the impact of peptide growth factors on gene expression and growth in cardiac myocytes themselves. References cited here are necessarily representative rather than inclusive, and recent reviews are indicated for most publications more than 2 years old.
Heparin-Binding and Transforming Growth Factors Exert Diverse Effects on Cell Phenotype and Are Members of Complex Multigene Families Fibroblast Growth Factors
Basic fibroblast growth factor (bFGF) was first identified by its ability to provoke proliferative growth of fibroblastic cells in tissue culture and subsequently was purified from diverse tissues including, more recently, the heart. 26 As expected from its widespread distribution, bFGF is a potent mitogen for diverse cell types, half-maximal at approximately 2 pM. In several lineages, bFGF also promotes morphology or specific gene products associated with a differentiated state, for example, type II collagen in chondrocytes. 2 The amino acid sequence of acidic FGF (aFGF) shares 55% identity with that of bFGF, and both peptides compete for receptor binding.2 Until recently, aFGF was detected only in the brain and retina (see References 7 and 8) , yet the biological effects of aFGF have seemed identical to A glossary of molecular biology terminology can be found in Circulation 1989;80:219-233. those of bFGF except for diminished potency.2 Both FGFs bind heparin, which has become useful in their purification, and heparin can selectively potentiate the action of aFGF, perhaps by preventing denaturation. Acidic and basic FGF possess differing affinities for two membrane constituents identified in some cells by cross-linking studies,2 a basis for potential divergence in their intrinsic biological activities. Basic and acidic FGF are prototypes of a large multigene family with members that include the int-2 oncogene, the hstIKS3 oncogene, FGF-5, FGF-6, and keratinocyte growth factor. 2, 9 Transforming Growth Factors Like the FGFs, the TGF,Bs are named on the basis of their first observed effect, in this instance, "transformed" growth in soft agar, comprise a supergene family, and exert multifarious effects on cell phenotype that vary with lineage and state of maturation.' TGF,31 and TGF,32 were first purified from human and porcine platelets, respectively, but also were independently discovered as regulators of differentiation secreted by other cell types. That the effects of TGF/31 on cell growth can be bifunctional is illustrated by its augmentation of certain colonies formed in agar, together with inhibition of mitotic growth of the same cells in monolayer cultures.' TGF,B1 alternatively provokes or inhibits growth, depending on cell age and the presence of coexisting growth factors.' Similarly, TGF,3 induces cartilage precursor cells to differentiate yet down-regulates differentiation of mature chondrocytes. Finally, TGF,3 exhibits both autoregulation and heterologous regulation of its expression, modulates the synthesis of growth factor receptors,10 and exerts antagonistic as well as cooperative effects with other growth factors.1'0 For example, TGF,31 inhibits growth induced by FGF in endothelial cells.
Structurally related peptides with far-reaching effects on development or cell function include Miillerian inhibiting substance, activins and inhibins, bone morphogenic proteins, and the insect protein dpp, which directs dorsal-ventral pattern formation.' One intriguing example of multifunctional action by these peptides is the recent finding that inhibin bA, which regulates release of gonadotropic hormones, is identical to an erythroid differentiation factor that induces hemoglobin in red cell precursors."1 A TGF,3 homologue, Vgl, thought to play a role in the induction of embryonal muscle,'2 is expressed in amphibian embryos. Other members of the TGF,B gene family, whose expression and functional properties that are as yet largely uncharacterized, include TGF/33, -,34, and -/35.1
Peptide Growth Factors in the Myocardium Cardiac Localization
A functional role for peptide growth factors in cardiac muscle has been suggested only recently, with increasing awareness of their existence in the heart and striking alterations of their expression in cardiac pathology. That TGF/31 is abundant in the normal rat heart was demonstrated in the course of its initial isolation.' Subsequent immunochemical studies have localized TGF,31 to the atrial and ventricular myocytes themselves in both neonatal and adult mice. 13 Intense staining for TGF,3 also is found in specialized conduction tissue of the atrioventricular node. Basic FGF activity also has been purified from myocardium by using heparin-affinity chromatography, and is associated with both cardiac myocytes and nonmuscle cells.6 Although, as in most cell types, bFGF messenger RNA (mRNA) abundance in freshly isolated cardiac myocytes can be insufficient for Northern blot analysis, aFGF is readily detected in neonatal rat cardiac myocytes and, by contrast, is not expressed by the corresponding mesenchymal cells.7 This agrees with the selective accumulation of aFGF in the extracellular matrix of cultured cardiac myocytes but not of cardiac fibroblasts.7 Greater concentrations of bFGF6 and TGFW,13 are found in atrial than ventricular muscle and might conceivably contribute to known disparities in each chamber's capacity to synthesize DNA in adulthood. Cardiac muscle may also be a locus for novel growth factors. Unique transcripts related to TGFW31 are found in the adult murine, rat, and porcine heart13'14 although it is not yet known if these in fact encode distinct proteins. Similarly, a mitogen with antigenic and limited sequence homology to bFGF has been isolated from bovine, porcine, and canine hearts, which is even more potent than aFGF. 8 Localization of peptide growth factors to the heart also has been demonstrated during cardiac embryogenesis. For example, embryonic chick heart expresses the recently discovered gene for TGF,83.1 TGF,B1 is observed by immunohistochemistry in the developing endocardial cushion and valves of embryonic mice.'3 Thus, akin to their demonstrated role in skeletal muscle ontogeny, discussed below, peptide growth factors might also participate in morphogenic events or the induction of particular cardiac cell lineages. The myocardial extracellular matrix,15 a potential source of FGF, or purified TGF1,16 each can provoke formation of atrioventricular valve primoridia in the embryonic chick heart. Finally, induction of cardiac muscle itself in the ventral mesoderm of Xenopus embryos can be negated either by excision of underlying endoderm at the beginning of gastrulation, or by injection of a dorsal mesoderm-inducing factor.17 These reports raise the possibility that deficient or excessive production of peptide growth factors in the fetal heart could contribute to defects of the atrioventricular cushion or other congenital malformations.
Myocardial Disease
In the adult heart, altered expression of growth factors accompanies myocardial ischemia and infarction, and argues for a potential role of these peptides in vascular or cardiac growth associated with these pathological states. Progressive coronary artery ste-nosis in the pig, produced by an ameroid constrictor, engenders the formation of extensive collateral vessels; this model of chronic ischemia is associated with increased levels of both TGF/3 and endothelial cell growth factor j3, a precursor of aFGF.18 Interestingly, the topographic distribution of these growth factor transcripts differs. TGF,B mRNA was localized by in situ hybridization to ventricular myocytes, whereas expression of endothelial cell growth factor was detected principally within coronary arteries. After infarction of rat myocardium, immunoperoxidase staining for TGF,B1 becomes undetectable in the infarcted myocytes yet increases progressively in surviving myocytes bordering the infarct.14 Upregulation of TGFf31 after infarction involves both elevated levels of the principal 2.4 kb mRNA and induction of the unique 1.9 kb transcript. Accordingly, it has been postulated that TGFJ3 may augment the response to injury, aid infarct healing, and play a role in compensatory hypertrophy of surviving myocytes. Alternatively, TGF,B might instead function to constrain growth, as inferred from its appearance only after the first round of cell division during liver regeneration.' After infarction, human myocardium also contains an angiogenesis factor with biological and immunologic properties similar to angiogenin. 19 For the moment, corresponding measurements of peptide growth factors during cardiac hypertrophy in vivo are unavailable. The likelihood of autocrine or paracrine factors in cardiac hypertrophy is implicit, however, in the ability of extracts from hypertrophied hearts to produce cardiac hypertrophy when infused in vivo.20
Oncogene-Encoded Proteins Convey Growth Factor Signals From the Surface Membrane to the Nucleus Growth Factors
The action of peptide growth factors in the heart as in other cells is understood to involve a cascade of proteins encoded by cellular (or "proto-") oncogenes, first identified as unexpected sequences of vertebrate genomic DNA corresponding to the acutely transforming genes of RNA tumor viruses21,22 ( Figure 1 ). Subsequently, procedures for gene transfer established that DNA from human tumors also could transform susceptible cells in culture, and led to the recognition of additional transforming genes, more distantly related to or distinct from those detected through correspondence to viral homologues. Expression of numerous cellular oncogenes has been observed in the heart, although in most instances uncertainty remains as to the relative contribution of myocytes, vascular smooth muscle, endothelium, interstitial cells, and other components of the organ.23-25 That proteins produced by cellular oncogenes might function to regulate normal growth was demonstrated by the fortuitous finding that oncogene-encoded proteins include previously recognized growth factors and their receptors.21-23 For and nuclear "third messengers," which link trophic signals to genomic responses. Each level of cascade is characterized by redundancy between and within complex multigene families of related proteins, by pleiotropic celland stage-specific actions, and by intricate patterns of heterologous and homologous regulation. The precise position of ras relative to other elements of this cascade is conjectural. Growth factor signal transduction ultimately also involves interplay with myc-like lineage determination proteins, homeobox proteins that govem pattem fornation, and "zinc finger" transcription factors. Components of this circuitry known to be expressed in myocardium and selectively induced during cardiac ischemia or hypertrophy are indicated in the text. example, sis encodes the B chain of PDGF,5 and erbB encodes the EGF receptor.21 As discussed previously, several transforming genes encode homologues of acidic and basic FGF, and the oncogene int-l might code for a novel growth factor. Conversely, bFGF itself does not correspond to a naturally occurring oncogene yet provokes a transformed phenotype when fused to a deregulated promoter of expression.26
Receptors
At least four structural classes of growth factor receptor have been identified, all of which phosphorylate proteins on tyrosine residues and share overall structure and sequence with certain oncogenic proteins.21 1) Like the erbB/EGF receptor gene, neu (erbB2) encodes a transmembrane protein with two extracellular cysteine-rich domains, the putative receptor for an unidentified ligand. 2) In contrast, both PDGF receptor isoforms resemble the oncogene proteins kit and fins, whose extracellular cysteines are dispersed and tyrosine kinase domain is divided by a long insert. Possibly resulting from duplication of an ancestral PDGF receptor gene, c-fins encodes the related receptor for a phagocyte growth factor, CSF-1; however, c-fms also is expressed in proliferating myoblasts. 22 3) The receptors for insulin and IGF-I are heterotetramers similar to the proteins v-ros and c-met.21,27 4) The FGF receptor likewise contains a tyrosine kinase domain but differs in other aspects of its structure. 28 Finally, dissimilar to each of these, the product of c-mas possesses seven transmembrane helices, resembling adrenergic, muscarinic, and other receptors that work through G proteins, and may encode a neuronal angiotensin II receptor.21
Coupling Proteins
Together with various membrane-associated and cytoplasmic protein kinases such as src and mos, respectively, ras proteins appear to propagate signals conferred by growth factor binding from the cell surface to the nucleus.21-23 The pivotal role of ras proteins was indicated by their ability to bind and hydrolyze GTP and their structural similarity to the more familiar G proteins. Conversely, many oncogenic ras proteins cannot hydrolyze GTP and might be expected to act as a constitutive growth factor signal. This postulated function has been corroborated by an elegant series of complementary approaches. Microinjection of recombinant ras proteins can serve as a surrogate for peptide mitogens, producing comparable changes in membrane ruffling and phospholipid hydrolysis, proving sufficient to provoke DNA synthesis and proliferation. Similarly, cells modified with an activated ras gene also exhibit decreased dependence on exogenous growth factors, increased inositol phosphate production, and altered differentiation.212229-32 A more classic GTP-binding protein, Gsw is mutationally altered in certain pituitary tumors and likewise directs augmented growth.33 In pheochromacytoma cells, maturation is induced by nerve growth factor, transforming ras genes instead promote a more differentiated state. 22 Conversely, microinjected antibodies to ras block both proliferation and differentiation triggered by growth factors.21,22 Physiological ras proteins, however, may be most abundant in cardiac muscle. 24 Thus, high ras expression can occur in a postmitotic organ. Indeed, H-ras abundance varies little with the state of growth or differentiation in other cell types including skeletal muscle.22 H-ras is expressed at similar levels in the embryonic, neonatal, adult, and senescent rat heart and varies little during hypertrophy produced by aortic constriction. 25, 34 As predicted from the proposed scheme for growth factor transduction, microinjection and overproduction of phospholipase C35 or protein kinase C21 also can substitute for exogenous mitogens, whereas antibody to 1,44inositol-diphosphate36 or protein kinase C21 prevents proliferation. Structural features of a phospholipase and protein kinase C are common to the oncogene proteins crk and raf, respectively.21 Furthermore, ligand binding to the PDGF receptor stimulates association of the receptor with c-raf and activates the c-raf kinase.37 Multiple src-like, ras, and protein kinase C genes exist,21,22 and it is conjectural to what extent any growth factor might act through particular combinatorial subsets of the potential pathways. Furthermore, the precise biochemical action of ras and its position within this apparent cascade relative to other oncogenes, membrane phospholipases, and other components also remain sources of controversy. Additional elements of the cascade for transduction of growth factor effects recently have been identified, including specific cellular substrates that become phosphorylated through protein kinase C after growth factor binding,38 as well as proteins that might regulate or confer the effects of ras.21 Finally, introduction of exogenous oncogenes into normal cells has been exploited to identify more directly the transcriptional mechanisms through which ras, other oncogenes, and extracellular growth factors ultimately alter cell phenotype.39,40
Intranuclear Mediators of Growth Factor Effects c-fos and c-jun
A set of oncogenes, whose prototypes are c-fos, c-myc, and c-jun, encodes proteins that are rapidly induced by growth stimuli, are found within the cell nucleus, and may be obligatory for proliferation and other growth factor effects to occur.21 23 Transient expression offos, myc, and jun is triggered by diverse trophic signals,22,41,42 that is, mitogenic agents such as growth factors, phorbol esters, or ras; differentiating factors; physiological stress; and activity-dependent events. fos is triggered in postmitotic neuronal cells by calcium influx associated with neuronal signaling,41 and distinct DNA sequences mediate induction of c-fos by calcium versus growth factors. 43 The demonstration that this nuclear oncogene can be elicited by ionic currents has led to the hypothesis that fos might couple membrane excitation to adaptive changes in gene transcription.41 Analogously, in cardiac muscle, hemodynamic stress and pharmacological agonists that produce cardiac hypertrophy each provoke the expression of growth factor-inducible nuclear oncogenes in ventricular myocardium.34'44'45 The c-fos oncogene is rarely detected in normal adult rat or mouse cardiac muscle25,46; however, c-fos can be evoked not only by a hemodynamic load34,45 but also by diverse pharmacological pathways such as by /Band a-adrenergic receptor agonists, histamine, or PGE1.23
Up-regulation of c-fos also accompanies cardiac aging in the 200-day-old rat.34
Procedures that introduce complementary "antisense"' sequences into cells, which bind and decrease the abundance of "sense" mRNA transcripts, can markedly inhibit expression of selected oncogene proteins.39 For example, blocking fos expression by antisense techniques inhibits DNA synthesis driven by serum growth factors and restores densitydependent growth to cells transformed by ras. 21, 22 Antisense methods also have been exploited to corroborate the still-hypothetic role of nuclear oncogenes in growth factor control of gene transcription. In cell lines transfected with exogenousfos genes,fos has been shown to transactivate the promoters of various other serum-responsive genes and to repress the promoter of fos itself, providing this cascade with elements of both positive and negative autoregulation. 39, 47 Though fos protein interacts with specific regulatory DNA motifs, both binding and its potent effects on gene expression now are known to be largely dependent on or potentiated by formation of a heterodimer between fos and a transcription factor previously known as AP-1, encoded by the oncogene c-jun. 48 The nuclear proteins fos and jun share a helical structure that aligns five leucine residues required for formation of the dimer ("leucine zipper") adjacent to a domain rich in basic amino acids required for DNA binding.48 Unlikefos, which downregulates its own expression, the jun oncogene is stimulated by jun protein, in part by changes that occur in preexisting jun molecules immediately after growth stimulation.47 Thus, a regulatory loop exists that might serve to sustain the signals triggered by growth factors. Furthermore, gene induction does not require de novo protein synthesis: protein-DNA contacts within the fos serum response element are not altered during growth factor induction or during subsequent repression,49 pointing toward alternative mechanisms such as modification of DNA-bound proteins or interaction with other components of a multiprotein complex. Identified members of the fosi jun family of proteins presently include c-fos itself, fosB, and thefos-related antigenfra-1, in addition to c-jun and its homologues, junB and junD. 48 Although neitherfos norfosB exhibits basal expression in adult murine heart,46 all three members of thejun multigene family have been detected in mouse myocardium at levels that were relatively high as compared with other organs.50 junB and junD mRNA levels were approximately fivefold to tenfold greater than c-jun. Unlike other fos and jun genes, junD is transcribed equally in quiescent and serum-stimulated fibroblasts50; despite the ability of exogenous junD to bind and activate serum-responsive promoters, its function, thus, is uncertain. Neither the developmental regulation of jun proteins in the heart, nor their potential regulation by hemodynamic events and other trophic signals, is currently characterized.
The apparent paradox thatfos itself increases after signals that produce either proliferative growth or differentiation may, in part, be explained by the existence of combinatorial permutations of these heterodimers46,48 and by increasing evidence for heterogeneous induction of nuclear oncogenes. For example, membrane depolarization induces c-fos and jun B but not c-jun in neuronal PC12 cells.51 A similar impediment to simple schemes for signal transduction is illustrated by the fact that TGF,B induces urokinase mRNA in lung adenocarcinoma cells yet decreases it in lung fibroblasts.' Analogously, TGF3 and bFGF exert reciprocal effects on endothelial cell evokes jun B but not c-jun in some cell lines.42 Such differences are likely to contribute to the bipolar effects of a growth factor in disparate cell lineages as well as the divergent responses of a given cell to varying growth factor ligands.
c-myc and the myc Homology Domain
Virtually all trophic events that induce c-fos also stimulate myc oncogenes, whose involvement in growth and differentiation is substantiated by gene transfer, microinjection, and antisense experiments similar to those discussed above.2'-2353,54 Localization to the cell nucleus and DNA binding by myc proteins were relatively early findings, and myc appears to alter the expression of several seruminducible genes.54 Compared with fos, however, myc protein weakly stimulates transcription in vitro,55 and myc does not form heterodimers with jun.56 Direct demonstration that myc might identify specific DNA sequences, as fos and jun proteins do, has been elusive. Nonetheless, the primary structure of myc protein predicts an amphipathic "helix-loop-helix" motif common to regulators of gene transcription, and its sequence is similar to achaete-scute, twist, and daughterless genes required for morphogenesis in Drosophila. 57 Moreover, myc homology has been identified in an increasing number of mammalian skeletal muscle "determination" genes including MyoDl, myogenin, and myf-5, which activate the myogenic program in pluripotent or fibroblastic cells.40,57,58 MyoDl requires the myc homology domain to function and, thus far, is indistinguishable from one putative transcription factor that interacts with the muscle creatine kinase enhancer element.4058 By contrast, other helix-loop-helix, myclike proteins are expressed in all mammalian or Drosophila cells.57 Importantly, each of these ubiquitous molecules (i.e., E12, E47, and daughterless) can form a specific sequence recognition complex with either MyoD or achaete-scute.57 This observation, in turn, demonstrates that the function of these tissuespecific enhancer-binding proteins is contingent on the formation of a dimer with heterologous proteins whose distribution is promiscuous. Although myc proteins themselves do not form heterodimers that interact with any of the DNA sites studied to date, the existence of this mechanism indicates the fundamental importance of a myc domain for the helixloop-helix enhancer-binding proteins and suggests the possibility that this class of transcription factors might complex with myc for interaction with enhancer sites that lie elsewhere.57 Conversion of embryonic cells to a muscle phenotype also has been produced using two oncogenes, v-ski59 and polyoma middle T,60 unrelated to c-myc.
In cardiac muscle, steady-state expression of c-myc declines exponentially during embryonic development,25 becomes activated in vitro by mitogenic serum25,61 or a,-adrenergic receptor agonists,62 and is reexpressed in vivo during hypertrophic growth triggered by pressure overload.344445 Reinduction of cmigration during in vitro angiogeneSiS,52 and TGF,8 myc after aortic constriction is greater in atria than in ventricles and greater in younger than in older animals,44 in parallel with the respective capacity to replicate DNA; however, c-myc remains inducible in cultured cardiac myocytes that have been differentiated for more than 2 weeks and fail to replicate DNA or divide in nominally mitogenic medium. 61 Thus, irreversible down-regulation of c-myc cannot be the basis for the loss of cardiac cells' ability to divide, and one or more functional pathways that transduce the effect of serum growth factors may persist in older cardiac muscle cells. Serum mitogens also provoke c-myc in postmitotic skeletal muscle cells that have undergone fusion and terminal differentiation. 63 Although such results illustrate that c-myc by itself need not be sufficient to serve as a surrogate for particular growth factor effects, exogenous myc genes delay or inhibit the differentiation of cultured skeletal muscle cells22'30'32 and provoke hyperplastic cardiac growth when expressed in the myocardium of transgenic mice (J. Swain, personal communication).
c-erbA
By contrast to nuclear oncogenes that are rapidly induced after growth factors bind to the cell surface, erbA encodes nuclear thyroid hormone receptors, whose ability to regulate myosin heavy chain expression entails intrinsic domains for ligandand DNAbinding. 64 Receptor isoforms produced by alternative mRNA splicing differentially affect myosin heavy chain transcription. Unlike oncogenes that are activated on mutation, the truncated viral derivative v-erbA functions instead as a constitutive repressor of thyroid hormone-dependent genes.65 A more direct role for growth factors in the nucleus has been postulated on the basis of evidence that each chain of PDGF possesses sequences that target the protein to intranuclear sites, suggesting a pathway alternative to secretion and surface binding.66 Nuclear targeting has also been demonstrated by bFGF and inferred for TGFf,4.1
Other Growth Factor-Induced Nuclear Proteins Additional growth factor-inducible genes have been identified through cloning strategies that exploit their inherently differing expression in stimulated versus quiescent cells. One of these, designated "early growth response" (EGR)-1, encodes a protein similar to the "zinc finger" transcription factors.67 Unlikefos, myc, orjun, EGR-1 is highly expressed in the myocardium and, interestingly, is also found in P19 embryonal carcinoma cells when a partially cardiac phenotype (i.e., spontaneous contraction and sarcomeric actin expression) is induced.67 Isolation of a zinc fingerlike transforming gene from human glioblastoma cells reinforces the notion that "oncogene-encoded proteins" might potentially include any protein that influences cell growth or differentiation if suitably activated. 68 Conversely, the molecular lesion for hereditary retinoblastoma inactivates the gene for a nuclear DNAbinding protein that suppresses the transformed phenotype.l Although its normal cellular targets are unknown, the protein forms complexes with nuclear transforming proteins of DNA tumor viruses. Loss of this gene product leads to the absence of TGFP3 receptors and failure of TGF/3-induced growth arrest.' Thus, the retinoblastoma susceptibility gene is the model for "recessive" oncogenes or "antioncogenes," which might mitigate or repress growth factor effects. It is noteworthy that one growth arrest-specific gene, gasl, isolated from quiescent NIH 3T3 cells (down-regulated by serum or v-fos) is highly expressed in adult heart. 69 Finally, one oncogene that extinguishes the ability of skeletal muscle to differentiate, SV40 large T antigen,70 by contrast is permissive for at least a partially differentiated phenotype in cardiac myocytes despite their dramatic growth.71 These disparities suggest the prediction that cardiac myocytes might possess responses to extracellular growth signals, such as peptide growth factors, which also differ from those of skeletal muscle.
Mechanisms for Growth Factor Control of Contractile Proteins and Ion Channels Are
Delineated in Skeletal Muscle Models Historically, skeletal myogenesis served as a favorable model system in which the impact of serum growth factors became evident, at least in part, because of the mutually exclusive relation between proliferation and differentiated gene expression.22 Permanent clonal cell lines exist, which could be induced to express muscle-specific genes after serum withdrawal, facilitating identification of the exact serum components that inhibit myogenic development. Moreover, the ability of myogenic cell lines to incorporate and express foreign DNA, transiently or stably, has been exploited to delineate regulatory motifs within numerous muscle-specific genes57,72 and to demonstrate that activated cellular oncogenes can suffice to inhibit or abolish muscle-specific gene transcription.2229-3240 Thus, for both biological and technical reasons, skeletal muscle has served as the archetype of growth factor control in striated muscle development. One mechanistic basis for regulation of muscle-specific genes by serum growth factors is suggested, in part, by evidence that a nuclear phosphoprotein that binds the major DNA sequence for muscle-specific expression of actin is indistinguishable from the "serum response factor" necessary for serum induction of c-fos.72 Even though cardiac muscle expresses a number of genes in common with skeletal myocytes including muscle creatine kinase and both sarcomeric a-actins, only a few of-the conclusions illustrated below also have been tested in cardiac muscle as yet.
Growth and differentiation properties can be reciprocally or independently regulated. Both bFGF and aFGF are potent mitogens for skeletal myoblasts that concomitantly block the myogenic phenotype in undifferentiated cells, apparently differing only in potency.22 '73 In contrast, TGFJ31 suppresses the induction of muscle-specific genes in the absence of proliferative growth.74,75 Divergence has been noted in the relative importance of each factor in particular cell lines. 22 Growth factor receptors and responses decline during developmental maturation. Although TGF,31 and bFGF also down-regulate the muscle phenotype in myocytes before terminal (irreversible) differentiation, myocytes committed to fusion and the postmitotic state appear to be refractory to the action of TGF,B1 and bFGF on muscle-specific genes.22,73-75 Muscle cell receptors for TGF/3122 and FGFs73 down-regulate dramatically on terminal differentiation. Functional receptors can persist, however, as shown by the ability of L6E9 myotubes to up-regulate fibronectin and collagen after treatment with TGF,8174 or c-myc after exposure to serum.63 Three additional lines of evidence support terminal differentiation as the cause and not the consequence of growth factor receptor down-regulation: loss of FGFresponsiveness precedes loss of receptor,73 the postmitotic phenotype dominates in heterokaryons with even one nucleus from a postmitotic muscle cell,73 and induction of N-ras in myotubes did not extinguish muscle creatine kinase expression. 31 Proteins of the sarcomere and sarcolemma can be extinguished in common by a single extracellular or intracellular signal. By itself, TGF(31 is sufficient to reversibly block expression of genes encoding numerous sarcomeric proteins,32'74 muscle creatine kinase,75 and the "slow" Ca2+ channel,32,76 as well as Na+ channels and dihydropyridine-insensitive Ca2+ channels that appear up to 60 hours before dihydropyridine-sensitive current.76 Together, these results resemble the consequences of activated H-ras or N-ras genes in skeletal muscle,22,29-32'40 suggesting that TGF,81 might act through ras to suppress a very early step in the myogenic pathway. Inhibition of differentiated gene expression by TGF,81 can occur, at least in part, by preventing the appearance or activity of muscle-specific DNA-binding proteins that modulate transcription. 58 Growth factors interact with genes that establish cell lineage. Because ras bFGF and TGF,B1 can inhibit the expression of MyoDl itself,77 and because an exogenous MyoDl gene overcomes the block to differentiation in myoblasts stably transfected with ras,40 the possibility has been suggested that suppression of a "determination" gene may suffice to downregulate the differentiated state in muscle. By contrast to this prediction, constitutive expression of MyoDl fails to prevent the suppression of musclespecific genes by bFGF,77 TGF/31,77 mitogenic medium,40 or ras transfected transiently40 (which might enable higher ras expression than in permanently transfected cells). Moreover, lower concentrations of TGF/1 suppress "downstream" musclespecific genes without diminishing MyoDl itself. 32 Thus, growth factor control of sarcomeric and membrane proteins can also occur through a mechanism independent of MyoDl mRNA abundance. Because tional events might confer its ability to transactivate muscle-specific genes.40
Early in development, inhibitors of myogenic differentiation paradoxically induce myogenesis and activate genes that govem pattem formation. Investigations of skeletal muscle ontogeny illustrate that responses to peptide growth factors vary not merely with cell type but also with the precise stage of differentiation. Whereas growth factors inhibit sarcomeric myosin and actin expression in cells committed to the skeletal muscle lineage, bFGF and endothelial cellderived growth factor (a precursor of aFGF) instead induce sarcomeric proteins in animal pole cells of early Xenopus embryos and cause the formation of primitive muscle like that normally induced by underlying vegetal pole cells.12'78 Mesoderm-inducing activity is also exhibited by aFGF and kFGF, and is potentiated by TGF,3, with preferential sensitivity to TGF,B2 versus TGF/31.78 Cooperative effects of bFGF and TGF,2 on muscle primorida are associated with induction of at least two homeotic genes, Mix.1 and Xhox.3, demonstrating possible interplay between mechanisms for growth factor signal transduction and those that govern pattern formation and morphogenesis in the developing embryo.'2
Atherosclerosis and Angiogenesis Growth Factor Expression in Smooth Muscle
Smooth muscle has occupied a key and consequential position in the elucidation of peptide growth factors' tropic effects. PDGF is the canonical example, with a pivotal role likely not merely in mitotic division by smooth muscle but also the more complicated process of atherosclerosis in vivo.5 From the finding that human PDGF A-chain transcripts are found both in the normal arterial wall where cell turnover occurs only slowly and in atherosclerotic plaques, it has been suggested that PDGF alone cannot account for augmented cell proliferation associated with atherosclerosis.79 At least seven genes coding for peptide growth factors are expressed in the rat aorta. 80 Diverse components of the vessel wall as well as blood-borne cells also produce peptide growth factors: endothelial cells, platelets, and macrophages each synthesize TGFJ31.1 Although TGF,81 inhibits the proliferation of endothelial cells,' its action on smooth muscle is bimodal, inhibition of mitotic growth at low cell density yet increased proliferation in confluent cells.' Moreover, TGF(31 also induces hypertrophy of smooth muscle cells, similar to that seen in hypertension. After the withdrawal of TGFf31, vascular smooth muscle cells become tetraploid, as occurs during cardiac hypertrophy in vivo.1
Evidence for the importance of heparin-binding FGFs as potential paracrine or autocrine factors in vascular biology includes their production by macrophages, endothelial cells, and smooth muscle cells themselves.2 The absence of a typical signal peptide sequence for secretion suggests the question of how MyoDl is a nuclear phosphoprotein, posttransla-bFGF can exit cells. Little bFGF is secreted by intact endothelial cells in culture, but bFGF is rapidly released from mechanically wounded cells.81 This provides at least a partial basis for the finding that, in atherosclerosis, injury can provoke proliferation.' Basic FGF that accumulates in the extracellular matrix of endothelial cells is a second potential source for release after injury.79 In contrast to either TGF,B1 or PDGF, bFGF is a potent mitogen for endothelial cells2 as well as smooth muscle. 79 Other peptides that are mitogenic for smooth muscle include EGF and IGF-1.79
Interconnected and Intricate Activities
Peptide growth factors have pleiotropic effects on endothelial cells, macrophages, and smooth muscle, in addition to the growth effects indicated by their name. For example, PDGF is a potent vasoconstrictor, as well as a mitogen.82 Conversely, endothelin first was defined and purified on the basis of its vasoconstrictor effects yet, in addition, induces smooth muscle mitosis. 83 TGF,l1 and (32, but not fibroblast growth factors, can deactivate macrophages and suppress the formation of cytotoxic oxygen metabolites.' Furthermore, peptide growth factors also influence gene expression by vascular smooth muscle. Type 1 collagen and fibronectin are induced by TGF,B1 (L. Goodman, personal communication), and heparin-binding growth factors cause the replacement of smooth muscle myosin heavy chains with nonmuscle myosin.84 Although PDGF and serum each provoke proliferation in quiescent aortic smooth muscle cells, distinctly different patterns of actin gene expression result. PDGF decreases a-smooth muiscle actin mRNA tenfold yet has no effect on f3-actin, whereas serum induces 13-actin but fails to alter a-smooth muscle actin expression.85 Thus, in contrast to skeletal muscle, proliferation and differentiated gene expression are not mutually exclusive in vascular smooth muscle.
That peptide growth factors regulate gene expression in the vessel wall is particularly relevant for the interplay of thrombotic and antithrombotic pathways. For example, bFGF stimulates production of tissue plasminogen activator (t-PA) by endothelial cells.2 Counteracting this, TGF/31 inhibits release of t-PA mediated by bFGF,1 and similarly, FGF, TGF,81, and EGF each stimulate synthesis of type 1 plasminogen activator inhibitor. 86 Both the abundance of growth factors within blood vessels and their action on vascular target cells are complicated by an intricate pattern of heterologous regulation. In vascuilar smooth muscle, TGF,31 induces PDGF-A, as well as interleukin-6 (L. Goodman, personal communication) and endothelin87;
PDGF-A is also provoked by angiotensin II, which induces c-myc oncogene expression and hypertrophy in smooth muscle.88 TGF,31 also is a potent chemoattractant for monocytes, an additional source of growth factor production or release.1 As examples of its concomitant antagonist effects, TGF,31 suppresses the proliferative response to PDGF85 and bFGF' in smooth muscle and endothelial cells, respectively, and blocks stimulation by EGF of c-myc (but not c-fos) in endothelial cells.10 In vivo, TGF,3 gene expression itself is stimulated in arterial blood vessels after balloon denudation.89 In deoxycorticosteronesalt hypertension, TGF,B mRNA increases threefold, whereas no such change occurs in the FGFs, IGF-I and -II, or either PDGF chain.80 Finally, in certain disease states, smooth muscle may possess altered sensitivity to growth factors, as evidenced by enhanced mitotic growth, together with increased expression of c-fos and c-myc in cultured aortic smooth muscle from spontaneously hypertensive rats. 90 Beyond their more simple function in smooth muscle mitosis, both TGF,3 and FGFs elicit the complex process of angiogenesis itself. Notwithstanding its predominant antiproliferative effect in monolayer cultures, like bFGF, TGF,3 can induce endothelial cells suspended in a collagen gel to form tubular vessellike structures.1 Furthermore, local inoculation of TGF,3 results in both fibrosis and new vessel formation.' Basic and acidic FGF also are angiogenic in vivo.2 Together, these studies begin to demonstrate the diverse properties of the blood vessel wall that are susceptible to regulation by peptide growth factors.
Peptide Growth Factors Provoke Fetal Gene Expression in Cardiac Muscle Cells Plasticity of Cardiac Gene Expression
Akin to the recognition of growth factordependent mechanisms in smooth and skeletal muscle cells, recent appreciation of peptide growth factor expression in the myocardium and its regulation in cardiac disorders contrasts with a presently much smaller body of evidence demonstrating direct effects of peptide growth factors on either cardiac myocyte growth or differentiated phenotype. Although the well-defined function of peptide growth factors in sarcomeric gene expression by skeletal muscle argues that cardiac myocytes also are likely targets for the action of these peptides, pertinent distinctions between cardiac and skeletal muscle development suggest the potential for lineage-specific disparities. Unlike skeletal muscle, cardiac myocytes synthesize tissue-specific proteins without exiting the cell cycle,61 much as smooth muscle cells continue to express a-smooth actin in mitogenic serum despite resumption of proliferative growth.85 Moreover, in cardiac muscle, uncoupling of DNA synthesis from mitotic division occuirs in the early neonatal period, and as a result, adult mammalian cardiac muscle cells are normally tetraploid or binucleated.61 Thereafter, adaptive growth proceeds by myocyte enlargement rather than mitosis. Finally, as cited above, the oncogene SV40 T antigen provokes sustained proliferation in cardiac myocytes yet is permissive for differentiated properties,7lwhereas this viral onco-gene blocks the differentiation of skeletal muscle cells.70 Although a molecular basis for these differences would be speculative, it may be relevant that neither MyoDl nor myogenin is detected in cardiac muscle cells. 40, 58 It is unknown whether a corresponding "determination" gene controls the onset of cardiac muscle development or the plasticity of cardiac gene expression during adaptive growth triggered by pressure overload. 44, 45 In vivo, the growth stimulus provided by a hemodynamic load provokes cardiac hypertrophy associated with remarkable plasticity of differentiated gene expression. Although other mechanisms such as alternative mRNA splicing also contribute importantly to protein diversity in the heart, numerous sarcomeric, cytosolic, and membrane proteins are encoded by multigene families whose transcription is sequentially induced and deinduced during cardiac maturation. Permutations induced by pressure overload include up-regulation of a characteristic ensemble of proteins as isoforms associated with the embryonic state. The hallmark changes, at least in rodent models, occur in contractile proteins of both the thick and thin filaments, that is, up-regulation of the "fetal" a-skeletal actin and P-myosin heavy chain, in tandem with down-regulation of the adult a-myosin heavy chain.45,91 However, it is still, in part, problematic whether these substitutions confer altered mechanical properties to the ventricle. As a result of their lesser ATPase activity, J3MHCs are thought to produce greater economy of contraction but diminished myocardial contractility. 91 In contrast, any anatomic or physiological consequences of fetal actin expression are unproven. Thus, we423 and others45 have proposed that recapitulation of the fetal program by altered load might be indicative of shared regulatory elements rather than adaptation per se. Hypertrophy, in effect, recapitulates ontogeny.
Furthermore, it has been questioned whether such transitions have equivalent significance in humans because ,BMHC predominates in the adult human ventricle. 92 Nonetheless, human myocardium, like rodent models, does remain able to modulate differentiated gene expression in the face of hemodynamic stress. As evidence, six illustrations follow: 1) further decline of the sporadic aMHCs in the ventricle; 2) reexpression of ,3MHC by the enlarging left atrium; 3) reinduction of atrial natriuretic factor and 4) atrial myosin light chains, the presence of which in the embryonic ventricle normally ceases some time after birth92,93; 5) the "slow-cardiac" sarcoplasmic reticulum Ca2+-ATPase gene, which is simply downregulated by pressure overload and for which no alternate isoform is known to exist either during cardiac myogenesis or hypertrophy94; and 6) an additional (fetal) ,BMHC epitope, which is observed within the ventricle in dilated cardiomyopathy.92 Thus, human myocardium even in the adult is susceptible to trophic signals that modulate tissuespecific gene expression. Conceivably, the conse-human hypertrophy might be produced by growth factor binding to cardiac muscle cells.
Growth Factor Withdrawal Enhances Differentiation in Cultured Cardiac Myocytes
Cardiac myocytes in culture have facilitated investigations of myocardial growth, physiology, and gene expression despite limitations including cellular heterogeneity, the absence of permanent cell lines, and their failure to maintain a fully differentiated phenotype. The fact that conventional monolayer cultures of cardiac myocytes in medium containing serum revert to less-differentiated properties in terms of both membrane and cytoskeletal proteins together with reports that even adult cardiac myocytes ultimately reinstitute DNA synthesis under such conditions have indicated that the phenotype of cultured cardiac myocytes might be, in many ways, anomalous. 61 Paradoxically, this historical limitation has contributed to the recent concept that specific constituents of serum, that is, peptide growth factors, indeed can alter growth and tissue-specific gene expression in cardiac muscle cells. First, withdrawal of peptide growth factors using serum-free media with precisely defined suppleineints can maintain (and advance) the differentiation of neonatal rat cardiac niyocyte cultures for up to 15 days. 61 In other preparations including adult rat cardiac myocytes, serum-free media also enable differentiated gene expressioni and structure to persist. 95 Conversely, undefined componeints of serum distinct from thyroid hormione and adrenergic receptor agonists stimulate cardiac nmyocyte enlargement and protein synthesis.96
During growth factor withdrawal for up to 2 weeks, reintroduction of serum successively elicits mitotic division, DNA synthesis uncoupled from proliferation (as in the newborn rat heart in vivo), or neither growth response,61 corresponding to the three phases of declining growth capacity observed in the rat heart in vivo. Concomitantly, mitosis is associated with down-regulation of both sarcomeric a-actins, whereas serum selectively up-regulates a-skeletal actin in older cultures in which neither cell division nor DNA synthesis is produced.61 Taken together, such data give credence to the prediction that polypeptide growth factors might have the capacity to control myocardial growth and phenotype.
Peptide Growth Factors Provoke Fetal Contractile Protein Gene Expression in Cardiac Myocytes
Recent investigations in our laboratory have analyzed the consequences of three specific peptide growth factors -TGFJ31, bFGF, and aFGFin neonatal rat cardiac myocytes initially differentiated by mitogen withdrawal.4 Treatment with TGF,81 for 24 hours altered the expression of both MHC and actin genes, in a pattern stronigly resembling that observed after pressure overload in vivo (Figure 2 ). Despite inclusioin of thyroxine in the serum-free medium, the adult (a) MHC was inhibited by two thirds with reciprocal inductioni of the "4embryonic" j3MHC quent pattern of fetal gene iiiduction in aninial and (approximately fourfold). Furthermore, unlike thyroid hormone, TGFI1 also provoked a concomitant increase in a-skeletal actin mRNA abundance. In contrast, little or no change occurred in a-cardiac actin transcript availability, which recalls the similarly unperturbed level of a-cardiac actin gene expression after a hemodynamic load. In keeping with effects in skeletal muscle involving the myogenic pathway but not mitotic growth,75 TGF/3 failed to affect myocyte protein and RNA content or to influence cell number. bFGF modulated the pattern of cardiac contractile protein gene expression, with results similar to those in TGF/31 both qualitatively and quantitatively. Unlike TGFf1, bFGF also stimulated protein content in the myocyte cultures yet did not elicit increased protein content in cardiac fibroblasts that had received similar exposure to the serum-free medium. Given the overall similarity between the actions of aFGF and bFGF in most other cell lineages including skeletal muscle,222 an unexpected outcome of this investigation was that the impact of aFGF on cardiac gene expression as well as cardiac growth might diverge dramatically from the responses shown to bFGF. Despite similarly reciprocal (but more potent) effects on the a and JMHC genes, aFGF instead down-regulated the genes encoding both cardiac and skeletal forms of a-actin. A third a-actin associated with adult vascular smooth muscle is expressed during normal cardiac myogenesis before a-SkA or a-CaA, which unlike the striated muscle a-actins, was up-regulated by all three growth factors including aFGF.4 Thus, aFGF stimulation appears to result in a phenotype ontogenetically more primitive than either bFGF or TGFf31. Interestingly, in this context, aFGF also initiated myocyte proliferation, an effect not seen in the parallel cultures of serum-starved cardiac fibroblasts.
These data demonstrate that cardiac myocytes possess complex, heterogeneous responses to three peptide growth factors, provide insights into previously described actions of serum on heart muscle cells, add to the known differences between cardiac and skeletal muscle development, and imply the potential for a paracrine or autocrine role of growth factors in pressure-overload hypertrophy. Further-more, these peptide growth factors may have a broader spectrum of regulatory activities in the heart than on contractile proteins alone, as suggested by evidence that each can stimulate ANF expression in cultured ventricular myocytes and inhibit the sarcoplasmic reticulum Ca2+-ATPase gene, consistent with the inference of a more generalized embryonic phenotype (T.G. Parker and M.D. Schneider, unpublished observations).
Preliminary data emerging from other laboratories confirm the ability of FGFs to induce growth in cultured cardiac myocytes.9798 Direct activation of protein kinase C is also sufficient to elicit DNA synthesis in cardiac muscle cells.99 Furthermore, paracrine factors produced by infiltrating monocytes are thought to be the basis for myocardial enlargement, fibrosis, and congestive heart failure in mice inheriting a v-ifs transgene, which is not expressed in cardiac myoeytes themselves. 100 Finally, as in other systems, TGFf31 might in fact suppress the trophic effects of other peptide growth factors.10' It is important to note, as such observations now accumulate, that specific outcomes are likely to be affected by experimental variables including coexisting growth factors, cell density, and, conceivably, contractile work. In human cardiac muscle, the role of peptide growth factors is somewhat more conjectural. Nonetheless, a recent study has shown convincingly that human fetal cardiac myoblasts can be maintained in culture and are induced to proliferate by bFGF together with IGE- 1.102 Conversely, withdrawal of mitogenic medium induced the expression of a-cardiac actin in ventricular myoblasts. To what extent this in vitro work might be translated to the intact heart in animals or humans awaits experimental verification.
Implications
The available data demonstrate that peptide growth factors can provoke fetal gene expression in cultured cardiac myocytes, similar to transitions elicited during adaptation to load. The inference of a generalized "embryonic" state is substantiated by each of the contractile protein genes examined to date, as well as by the induction of ANF. It should be emphasized, however, that only a partial subset of the cardiac phenotype has been examined thus far. Moreover, potential interactions among these peptides, their interplay with other agonists such as norepinephrine or thyroid hormone, and the detailed circuitry of growth factor signal transduction each remain to be defined for cardiac myocytes. The possible existence of autocrine or paracrine pathways that might modulate cardiac growth and gene expression during adaptive hypertrophy suggests a number of intriguing implications ( Table 1) . 1) Differences in the topographic distribution of fetal actin and MHC transcripts occur after imposition of a hemodynamic load,91 to which local fluctuations of growth factor production or release might contribute, at least in principle. Because growth factors accumulate within the myocardium and might be rapidly released on cardiac injury or stress, de novo synthesis of these peptides may not be required for the initial response to injury. 2) In vitro, expression of 8MHC and ANF in the absence of a-skeletal actin can be provoked by aFGF, and induction or release of this peptide growth factor might explain, in part, "adaptive" changes in gene expression that persist in the compensated stage of cardiac hypertrophy despite return of ventricular wall stress to normal.91 Thus, regardless of the precise initiating mechanisms in pressure-overload hypertrophy, peptide growth factors may sustain and amplify the signal imposed by load. 3) As with adrenergic receptor agonists, these effects might differ with developmental stage, and results observed in neonatal cells may not predict the responses of adult myocytes. Age-related changes in growth factor production or responsiveness might influence the capacity of cardiac muscle to undergo adaptive growth and modulate gene expression. Analogously, differential sensitivity to aFGF would suffice to explain previous evidence that the effects of serum on myocyte growth and actin gene expression during differentiation in vitro vary in a sequential program that resembles the transition from hyperplastic to hypertrophic growth in vivo.61 4) It is plausible to suggest that growth factor production be examined, similarly, in myocarditis, cardiomyopathy, or transplant rejection.100 5) In addition to long-term changes on the basis of altered contractile protein biosynthesis, certain growth factors modify contractility acutely, at least in smooth muscle.82 Similar to smooth muscle, growth factor effects may extend beyond growth and gene expression, as evidenced by the ability of stimulators of protein kinase C to alter Ca21 current in cardiac muscle103 and the positive chronotropic effect of epidermal growth factor.'04 6) bFGF prevents the death of neurons after transection of their axons in vivo, demonstrating in at least one lineage that this peptide also supports cell survival after injury. 105 Finally, the aggregate effects of peptide growth factors in the intact myocardium might be expected to entail multiple cell types apart from the myocytes themselves and are unlikely to be predicted fully from the properties of single components in cell culture. In vivo investigations might better determine the ability of growth factors to affect the growth of vascular smooth muscle, endothelial function, fibrosis, or lymphocyte chemotaxis in normal and diseased myocardium. A role for TGF,B in infarct healing can be proposed on the basis of its ability to accelerate tensile strength and collagen accumulation in other models of tissue injury.' Despite remarkable progress in application of hematopoietic factors to anemia and immunodeficiency,106 the analogous use of peptide growth factors in cardiac repair remains opportune but unexplored. 
